Thrombocytopenia Therapeutics Development Pipeline Review, H2 2015 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mr3x6h/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Thrombocytopenia Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia Prostate Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Thrombocytopenia Prostate Cancer Overview
3. Therapeutics Development
4. Pipeline Products for Thrombocytopenia Prostate Cancer - Overview
5. Pipeline Products for Thrombocytopenia Prostate Cancer - Comparative Analysis
6. Thrombocytopenia Prostate Cancer - Therapeutics under Development by Companies
7. Thrombocytopenia Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
8. Thrombocytopenia Prostate Cancer - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Thrombocytopenia Prostate Cancer - Products under Development by Companies
13. Thrombocytopenia Prostate Cancer - Products under Investigation by Universities/Institutes
14. Thrombocytopenia Prostate Cancer - Companies Involved in Therapeutics Development

• 3SBio Inc.
• Amarillo Biosciences, Inc.
• Amgen Inc.
• Arcturus Therapeutics, Inc
• aTyr Pharma, Inc.
• Baxalta Incorporated
• Bayer AG
• BioLineRx, Ltd.
• Boehringer Ingelheim GmbH
• Bolder Biotechnology, Inc.
• Bristol-Myers Squibb Company
• Cellerant Therapeutics, Inc.
• Eisai Co., Ltd.
• Hansa Medical AB
• Immunomedics, Inc.
• Intas Pharmaceuticals Ltd.
• Jiangsu Hengrui Medicine Co., Ltd.
• Merck & Co., Inc.
• Momenta Pharmaceuticals, Inc.
• Myelo Therapeutics GmbH
• Neumedicines Inc.
• Novartis AG
• Pfizer Inc.
• PhytoHealth Corporation
• Prophylix Pharma AS
• Protalex, Inc.
• Rigel Pharmaceuticals, Inc.
• Shionogi & Co., Ltd.
• STATegics, Inc.
• ViroMed Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/mr3x6h/thrombocytopenia